Article Text

Original research
‘A sword of Damocles’: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study
  1. Charlotte Logeman1,2,
  2. Yeoungjee Cho3,4,
  3. Benedicte Sautenet5,
  4. Gopala K Rangan6,7,
  5. Talia Gutman1,2,
  6. Jonathan Craig8,
  7. Albert Ong9,
  8. Arlene Chapman10,
  9. Curie Ahn11,
  10. Helen Coolican12,
  11. Juliana Tze-Wah Kao13,14,
  12. Ron T Gansevoort15,
  13. Ronald Perrone16,
  14. Tess Harris17,18,
  15. Vincent Torres19,
  16. Kevin Fowler20,
  17. York Pei21,
  18. Peter Kerr22,
  19. Jessica Ryan22,
  20. David Johnson23,24,
  21. Andrea Viecelli3,25,
  22. Clair Geneste26,
  23. Hyunsuk Kim27,
  24. Yaerim Kim28,
  25. Martin Howell29,30,
  26. Angela Ju1,2,
  27. Karine E Manera1,2,
  28. Armando Teixeira-Pinto1,2,
  29. Gayathri Parasivam31,32,
  30. Allison Tong1,2
  1. 1School of Public Health, The University of Sydney, Sydney, New South Wales, Australia
  2. 2Centre for Kidney Research, Westmead Hospital, Westmead, New South Wales, Australia
  3. 3Australasian Kidney Trials Network, University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia
  4. 4Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
  5. 5Department of Nephrology Hypertension, Centre Hospitalier Régional Universitaire de Tours, Tours, France
  6. 6Centre for Transplant and Renal Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
  7. 7Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales, Australia
  8. 8College of Medicine and Public Health, Flinders University Faculty of Medicine, Nursing and Health Sciences, Adelaide, South Australia, Australia
  9. 9Academic Nephrology Unit, The Henry Wellcome Laboratories for Medical Research, University of Sheffield Medical School, Sheffield, UK
  10. 10Department of Medicine, University of Chicago, Chicago, Illinois, USA
  11. 11Internal Medicine, Seoul National University, Seoul, South Korea
  12. 12Head Office, Polycystic Kidney Disease Foundation of Australia, Sydney, New South Wales, Australia
  13. 13School of Medicine, Fu Jen Catholic University Hospital, New Taipei City, Taiwan
  14. 14Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  15. 15Faculty of Medical Sciences, University Medical Center Groningen, Groningen, The Netherlands
  16. 16Division of Nephrology, Tufts University School of Medicine, Boston, Massachusetts, USA
  17. 17Head Office, PKD International, Geneva, Switzerland
  18. 18London Office, PKD International, London, UK
  19. 19Department of Nephrology and Hypertension, Mayo Clinic, Rochester, New York, USA
  20. 20Kidney Health Initiative, The Voice of the Patient, Washington, DC, USA
  21. 21Divisions of Nephrology and Genomic Medicine, University of Toronto, Toronto, Ontario, Canada
  22. 22Nephrology, Monash Medical Centre Clayton, Melbourne, Victoria, Australia
  23. 23Department of Renal Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
  24. 24Australasian Kidney Trials Network, The University of Queensland, Saint Lucia, Queensland, Australia
  25. 25School of Medicine, University of Queensland, Brisbane, Queensland, Australia
  26. 26Department of Nephrology and Clinical Immunology, Centre Hospitalier Régional Universitaire de Tours, Tours, France
  27. 27Internal Medicine, Seoul National University Hospital, Jongno-gu, South Korea
  28. 28Department of Internal Medicine, Keimyung University College of Medicine, Daegu, South Korea
  29. 29Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
  30. 30School of Public Health, University of Sydney, Sydney, New South Wales, Australia
  31. 31Discipline of Genetic Medicine, The University of Sydney Medical School, Sydney, New South Wales, Australia
  32. 32Clinical Genetics, The Sydney Children's Hospitals Network Randwick and Westmead, Westmead, New South Wales, Australia
  1. Correspondence to Charlotte Logeman; charlotte.logeman{at}sydney.edu.au

Abstract

Background and objectives Presymptomatic testing is available for early diagnosis of hereditary autosomal dominant polycystic kidney disease (ADPKD). However, the complex ethical and psychosocial implications can make decision-making challenging and require an understanding of patients’ values, goals and priorities. This study aims to describe patient and caregiver beliefs and expectations regarding presymptomatic testing for ADPKD.

Design, setting and participants 154 participants (120 patients and 34 caregivers) aged 18 years and over from eight centres in Australia, France and Korea participated in 17 focus groups. Transcripts were analysed thematically.

Results We identified five themes: avoiding financial disadvantage (insecurity in the inability to obtain life insurance, limited work opportunities, financial burden); futility in uncertainty (erratic and diverse manifestations of disease limiting utility, taking preventive actions in vain, daunted by perplexity of results, unaware of risk of inheriting ADPKD); lacking autonomy and support in decisions (overwhelmed by ambiguous information, medicalising family planning, family pressures); seizing control of well-being (gaining confidence in early detection, allowing preparation for the future, reassurance in family resilience); and anticipating impact on quality of life (reassured by lack of symptoms, judging value of life with ADPKD).

Conclusions For patients with ADPKD, presymptomatic testing provides an opportunity to take ownership of their health through family planning and preventive measures. However, these decisions can be wrought with tensions and uncertainty about prognostic implications, and the psychosocial and financial burden of testing. Healthcare professionals should focus on genetic counselling, mental health and providing education to patients’ families to support informed decision-making. Policymakers should consider the cost burden and risk of discrimination when informing government policies. Finally, patients are recommended to focus on self-care from an early age.

  • genetics
  • nephrology
  • medical education & training
  • mental health
  • paediatric nephrology
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Strengths and limitations of this study

  • The focus groups allowed in-depth exploration of patients’ views on presymptomatic testing for autosomal dominant polycystic kidney disease and helped to understand their decision-making process.

  • The number of participants and the diversity was a strength in this study, including 154 participants across Australia, France and Korea from both stakeholder groups relevant to this study (caregivers and patients).

  • Research limitations are common to qualitative research methodology in that the data are not generalisable and are restricted to the expressed thoughts of participants.

  • We acknowledge sensitive topics may be discussed at the focus groups and some views may have been suppressed in the focus group setting.

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and affects about 10% of patients receiving kidney replacement therapy.1 Early phase of ADPKD is often asymptomatic but the development of kidney cysts leads to increased kidney volume, reduced kidney function and eventually follows a relentless course towards end-stage kidney disease.2–8 Clinical management involves pharmacological and lifestyle interventions to control hypertension, slow the progression of cysts, manage complications (kidney and extra-kidney manifestations) and maintain quality of life (QoL).9–11

Diagnosis of ADPKD is usually based on family history, ultrasonography, CT or MRI.12 Testing, however, can facilitate the diagnosis of ADPKD in patients whose kidney phenotypes are atypical or asymptomatic, and in patients with unknown family history. It may also help identify living donors for kidney transplantation.13–15 However, testing has not historically been part of routine care and remains controversial in some countries. Typically, countries used to offer testing when a diagnosis is needed to be confirmed in young patients with unknown family history, for family planning, to determine eligibility for kidney donation, or when the disease presents in childhood or adolescence but testing in adults is overall accepted and encouraged.16 In some countries in Europe and Asia, access to asymptomatic or presymptomatic testing is very restricted or not available.17–20

For the scope of this paper, testing may include any strategy used to identify the presence of ADPKD prior to symptom onset (including genetic tests, blood tests, imaging such as ultrasound, CT, MRI, and so on).13 While testing for ADPKD has the potential to support early intervention, patients can suffer from anxiety and depression from being diagnosed prior to the onset of symptoms.21–24 There are also concerns about potential discrimination with employment and obtaining life insurance, and strains on social and familial relationships.16 The genetic aspect of family planning is emotionally challenging as patients contend with guilt and uncertainty in pursuing parenthood.25 Decision-making about testing is ethically challenging with psychosocial implications, and requires an understanding of the patients’ attitudes, priorities and perspectives of testing. The aim of this study was to describe patient and caregiver perspectives on the value and risks of testing to support the development of strategies and interventions for testing for ADPKD that address their values and needs.

Methods

This focus group study was conducted as part of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) initiative.26 This study is focused on perspectives of patients on testing for themselves and/or their children. We used the Consolidated Criteria for Reporting Qualitative Research to report the study.27

Participant recruitment and selection

Participants were recruited across eight centres in Australia (n=3), France (n=4) and Korea (n=1). Participants were eligible if they spoke English (Australia), French (France) or Korean (Korea), were over 18 years old and diagnosed with ADPKD, or a caregiver. Caregiver refers to family member or support person and not their healthcare professional. We purposively sampled participants to capture a diverse range of demographics (age, gender, employment status) and clinical characteristics (stage of chronic kidney disease, age of diagnosis, current treatment, comorbidities and complications). Recruiting clinicians identified patients with ADPKD who could also invite their caregivers. Participants and researchers had no prior relationship. Participants were given information packages to be able to provide informed consent and received reimbursement (US$25—equivalent in local currency) for travel expenses.

Patient and public involvement

The SONG-PKD initiative26 was developed to ensure outcomes in trials are relevant to patients and other stakeholders. The SONG-PKD Steering Group comprises a multidisciplinary team of healthcare professionals and patients with PKD and was aimed to ultimately develop a core set of outcome domains informed by all stakeholders (including patients) to be reported in all trials in patients with ADPKD.26 Patients on the Steering Group were involved in the initial planning and design of the study. Purposive sampling was done across different centres and patients were able to invite any other patients who would be interested to participate. All participants were invited to be involved in the following step of SONG-PKD which involved completing a Delphi survey.26 Results of this survey will be emailed to all participants. The general public were not involved.

Data collection

The 2-hour focus group discussions were conducted from June to November 2017 until data saturation. Data saturation was achieved when CL, YC and AT agreed that little or no new concepts were arising from subsequent focus groups. We developed the question guide from the literature and with input from the research team (online supplemental material and methods).25 28 29 Focus groups were convened in a venue external to the hospital and facilitated by one investigator (English—AT (researcher), TG (researcher), YC (academic nephrologist); French—BS (academic nephrologist); Korean—YK (academic nephrologist)). Focus groups were designed with the intent to have a broad range of demographic and clinical characteristics (including patients/caregivers, age). We did not consider severity of symptoms a priori. We did not separate patients from a caregiver as they preferred to participate in the same group. A cofacilitator recorded field notes. All discussions were audio recorded and were transcribed.

Data analysis

All transcripts were entered into HyperRESEARCH (V.3.7) for analysis and coded line by line, in the original language and then translated for investigator triangulation, by CL (researcher) (English, French) and HK (academic nephrologist) (Korean) using thematic analysis and drawing on principles from grounded theory to identify concepts related to perspectives on testing for ADPKD.30 From grounded theory, we conducted initial coding (memoing) and line-by-line coding of the data, used constant comparison within and across the transcripts and inductively identified concepts and themes. In accordance with thematic analysis, we identified initial concepts and grouped similar concepts into themes. Codes were grouped by similar concepts into themes and subthemes which were discussed and revised with AT/TG/YC/BS/YK who independently read the translated transcripts. To ensure reliable interpretation of the translated transcripts, CL and HK were available to give more context of the quotes. Investigator triangulation ensured that the analysis captured the full range and breadth of the data.31

Results

In total, 154 participants (120 patients, 33 caregivers) participated in 17 focus groups across Australia, France and Korea. The demographics are shown in table 1. Participants’ age ranged from 19 to 78 years (mean age 54.5 years) and 67 (42%) were men. Most patients were diagnosed between the ages of 21 and 40 years and the majority of patients were predialysis (n=76, 61%), followed by transplant recipients (n=31, 26%) and those on dialysis (n=19, 13%). The majority of caregivers defined themselves as the spouse or partner of the patient (n=24, 71%), but also included child (n=2, 6%), daughter-in-law (n=1, 3%), parent (n=4, 12%) and sibling (n=1, 3%). Reasons for declining to participate included having other commitments and being too unwell to participate.

Table 1

Participant demographic characteristics

Five themes were identified with both patients and caregivers contributing to the concept unless otherwise stated: avoiding financial disadvantage, futility in uncertainty, lacking autonomy and support in making decisions, seizing control of well-being and anticipating impact on QoL. Subthemes are described in the following section. Illustrative quotations for each theme are provided in table 2. The conceptual links among themes are depicted in figure 1.

Figure 1

Thematic schema. Participants felt that their ability to take control of their health was influenced by how prepared they were financially and was hindered by the unpredictable nature of their disease symptoms (indicated by the solid lines). Participants often felt that they were conflicted in whether or not they wanted to be tested for polycystic kidney disease (PKD). This decisional uncertainty (indicated by the dotted lines) was prompted by the uncertainty in participant symptoms, whether they felt capable of seizing their health, how they anticipated the impact on PKD on the quality of their life and whether or not they had support and autonomy in their decisions. ADPKD, autosomal dominant polycystic kidney disease.

Table 2

Selected illustrative quotations

Avoiding financial disadvantage

Insecurity in the inability to obtain life insurance

Some participants (specifically caregivers) were concerned about patients being labelled as ‘high risk’ when assessed for life insurance and expected they would pay higher premiums, be unable to obtain insurance or be ‘dropped’ by their insurance provider. They suspected they would be unfairly penalised for a disease that may not manifest. For this reason, some did not disclose ADPKD or avoided confirmatory tests—‘Don’t get it confirmed, just live your life as long as you can without being diagnosed’ (caregiver, France). Parents worried that limited insurance would restrict their children from travelling and from attending school camps.

Limiting work opportunities

Some patients feared discrimination from employers who could deny or dismiss them because of a diagnosis. Some worried that the disease would impair their physical ability to perform at work. Parents considered how the risks of early diagnosis through testing may jeopardise work opportunities for their children—‘[my] doctor advised me to organize a genetic test for [my son] … but then I think if his test result comes back positive … this may have a negative impact on his ability to work in future’ (Australia). Some refused tests and avoided disclosing their medical history to protect employment prospects.

Financial burden

Some presymptomatic participants wanted to undergo testing for ADPKD, but the cost was prohibitive, particularly for participants in Korea—‘Genetic testing raises concerns about associated cost…. spending a lot of money in advance is a burden’ (Korea). Some believed that a history of ADPKD warranted reimbursement from the government to improve equity of access to testing.

Futility in uncertainty

Erratic and diverse manifestations of disease limiting utility

The symptoms of ADPKD were regarded as unpredictable, such that a diagnosis would not provide useful information about symptom burden and prognosis. Patients and caregivers believed it was unnecessary to be concerned until symptoms become apparent—‘[confirmatory testing] was a big call to make for something that could never ever actually develop’ (Australia).

Taking preventive actions in vain

Participants who had been diagnosed through screening felt frustrated when attempts to minimise disease progression (eg, with antihypertensive medications or smoking cessation) proved futile. Some felt helpless and perceived that testing prior to experiencing symptoms was useless since they were powerless to change the unpredictable course—‘There’s no benefit to knowing early. There is nothing they can do to change the outcome, it’s going to happen in its own time’ (Australia).

Daunted by perplexity of results

Some parents worried that their child would be overwhelmed in trying to comprehend or interpret the results from testing and that it would create ‘a sword of Damocles over [their] head causing worry, anxiety, depression and even posttraumatic stress disorder’ (France).

Unaware of risk of inheriting PKD

The threat of transmitting the disease to their children caused decisional conflict about testing. Some felt they would be more empowered by knowing the results—‘Knowing that you’ve got a possibility of a child having a disease is good, it can help you with other decisions’ (Australia). Others struggled with the uncertainty of the impact of tests on decisions about family planning—‘probably the biggest impact in my life at the moment is whether or not I want to consider passing on the PKD gene’ (Australia). For parents who were diagnosed after having children, they believed that the diagnosis would not have impacted their decisions and were aware of options such as preimplantation genetic diagnosis—‘Genetically if there was some way of knowing that I was going to pass it on would I take that, or would I just go ahead and have the child? […] I would have the child’ (Australia).

Lacking support and autonomy in decisions

Overwhelmed by ambiguous information

Participants felt ‘completely in the dark’ about testing. They struggled with conflicting opinions, such as what age to get screened, and some felt misled by clinicians—‘I remember the specialist [saying to mum], “girls don’t get polycystic kidney disease so you’re fine having two girls,” so my sister and I lived in oblivion until I was 42’ (Australia). Some thought that clinicians did not provide adequate genetic counselling. In Australia, some were unaware that a genetic test was available and felt they should be informed. They searched for information on the internet and asked other family members with ADPKD but were disappointed by a general lack of information.

Medicalising family planning

Some participants regretted having tests when they were advised against having children—‘[The doctors said] “don’t reproduce, that will stop the disease”’ (Australia). Some diagnosed through screening feared judgement from clinicians and felt pressured against having children. Others appreciated the direct advice in family planning to support their decision—‘[The doctors] told me “don’t do it”. And I made the choice—no kids’ (France). Some resisted prenatal testing to avoid having to confront decisions about termination of pregnancy—‘if genetic tests find PKD, are you going to abort the fetus? No. If I found out early with fetus in utero, I will feel guilty and have bad feelings’ (Korea). Some participants in France thought prenatal testing was useless because abortion was illegal—‘When he was in utero, I wanted to abort. At the time, it was not possible’ (France).

Family pressures

Some thought they should convince their family to get tested—‘From the moment I found that I had it, I wrote to all my relatives, and said, “Get screened”’ (Australia). Some parents expected that testing would motivate behaviour change to maintain health, and were frustrated when their child did not demonstrate effort to protect their kidney health—‘I keep nagging him to see a doctor, see a specialist, and he goes yeah, doctor said my kidneys are alright’ (Australia). For some, tests on children were a collective ‘family concern’ and decision.

Seizing control of well-being

Gaining confidence from early detection

An early diagnosis through testing was thought to provide an opportunity for participants to take control of their health by modifying their diet and taking preventive medications, such as antihypertensive agents. Participants were empowered to monitor their health vigilantly and gained confidence in their ability to preserve their QoL—‘Going to the doctor regularly, just getting your blood pressure checked, because they say that if you can keep your blood pressure under control, they [kidneys] might not fail’ (Australia). For parents with a child with ADPKD, an early diagnosis motivated them to educate and ‘reinforce the importance of dietary health’ (Korea) in their children.

Allowing preparation for the future

An earlier diagnosis through testing enabled patients to mentally prepare for potential symptom burden and make lifestyle changes (including financial and career planning) to protect their QoL and avoid stress—‘Forewarned is forearmed’ (Australia). Some participants (particularly on dialysis) regretted not getting tested as they would have maximised their time while asymptomatic—‘If we had been educated earlier, we would not have worked so hard, we would have had a holiday, all those things would have been done so we had no regrets later’ (Australia).

Reassurance from family resilience

Some observed their parents’ optimism and resilience while on dialysis or with a transplant, and this strengthened confidence in their decision to be tested. Some appreciated that testing was more accessible for their children—‘now any of my family can go and get it done’ (Australia).

Anticipating impact on QoL

Reassured by lack of symptoms

Some participants were not interested in testing because their QoL had not been affected. They questioned ‘well do I actually have it’ and did not worry about their disease or testing—‘I have not had any major problems related to the disease’ (France). Some parents were not concerned with testing or genetic transmission as they believed their child would not suffer a disadvantaged life because they had not.

Judging the value of life with ADPKD

Some parents believed they would have decided against having children if they had been tested because ADPKD had caused their family to suffer—‘If I knew [that I had PKD], you would not be here’ (France). Some participants respected their parents’ decisions to have children but questioned that if they had had been tested ‘would I exist today?’ Some did not see the merit in testing as they valued their lives regardless of ADPKD—‘You’ve got to be pretty careful in that area because you create beings that are adding quite a bit of value to society’ (Australia).

Discussion

For some patients with ADPKD and caregivers, testing provided an opportunity to gain certainty about their health status, foster motivation and confidence for self-management, prepare mentally and financially for the onset of symptomatic disease and seek support from family. However, others perceived testing as futile because they perceived preventive measures had little impact, and the onset and course of ADPKD were unpredictable. They were also concerned about interpreting the results and the implications for their current and future life, which could cause unnecessary worry and anxiety, particularly with regard to family planning. The costs incurred in accessing testing and the potential financial discrimination they expected to endure would impose substantial constraints on their lives and futures.

Overall, the perspectives of patients and caregivers were similar as they felt inadequately equipped and conflicted in making decisions, which was exacerbated by a lack of support and information and perceived pressure from family and healthcare professionals. They were also uncertain about the severity of the symptom burden, and it was difficult to judge the value of life with ADPKD. Patients who witnessed intense suffering in their family members with ADPKD were inclined to refuse testing to avoid becoming anxious about their future and did not expect that the diagnosis would increase their sense of control. Lack of support has been recognised and, through discussions with specialists and patient advocates, this led to the development of a route map for ADPKD (available in three languages) intended to help patients and all stakeholders navigate through the services available to them (including genetic testing, diagnostic, management and treatment options).18

The variability in policies across the countries and parent-child roles may also explain some differences in perspectives. The diagnosis of ADPKD using methods other than genetic testing is routinely offered as the latter is not readily available or accessible in many countries. The cost of testing was of particular concern to patients in Korea, which may reflect the fact that testing is not funded by the government.32

This has led to an increase in direct-to-consumer genetic testing, which has negative ramifications because the public is often unaware of their clinical and social implications.32 Korean patients were particularly concerned about the cost burden of the disease and expressed that they did not understand the added value of paying for a presymptomatic ultrasound test if cysts may develop later in life. A recent study showed that more than 70% of Korean patients believed that genetic testing should be included in Korea’s national health testing programme so these services can be provided at little expense.33 In Australia, access to dialysis and transplantation is provided to all citizens via government-funded Medicare system.34 Transplantation is primarily limited due to insufficient kidney donors available to meet the number of potential recipients on the organ waiting list.34 Dialysis in Korea has also been covered since 1989 and this is similar in France.35 36 In France, genetic testing is not routinely offered to patients, although some could have free access to genetic testing (eg, if they were enrolled in the Genkyst observational cohort study37). In regard to legislative protection, Australia, France and Korea have comprehensive provisions pertaining to consent, autonomy and integrity of the person tested.38 In France, refusal of fetal testing for ADPKD may be due to fear of genetic transmission and the illegality of termination of pregnancy after 12-week conception due to ADPKD.39 No participants mentioned preimplantation genetic diagnosis, which highlights an information gap between countries. Variable perspectives can also be noted depending on the role of the participant regardless of their country of residence. In previous studies, parents have reported largely positive attitudes towards testing for children, while some children became more concerned about their health or the health of their family members.40 41 Younger patients expressed more anxiety around a diagnosis because they feared it could limit their future and were anxious about how quickly their health would decline.

Similar perspectives on testing have also been noted with other later onset progressive conditions including Huntington disease, characterised by a motor and cognitive deterioration with unpredictable prognosis leading to similar decisional uncertainty in views about testing.42–44 For patients with Huntington disease, family members could be perceived to have a supportive role or put pressure on making decisions in terms of being presymptomatically tested. They considered the consequences of sharing or withholding information about the diagnosis.45 Some refused testing to avoid unnecessary anxiety before they experienced symptoms of the disease.45

Our findings are consistent with the concepts of multigenerational transmission process in family system theory, which emphasises that an individual’s behaviour is inextricably connected with the attitudes and behaviours learnt from their family.46 47 The multigenerational transmission process can help explain how decisions about testing can be shaped by observing the extent to which family members (particularly parents) suffered the symptoms of ADPKD.46 Some patients believed that their experience might be different from those of their family members and were uncertain about the chance of genetic transmission in family planning, while others were influenced by the adverse impact that ADPKD had on their family.

Our study spanned three countries and provided in-depth, diverse and novel insights about testing for ADPKD from a relatively large sample of patients and their caregivers purposively selected to include a range of demographic characteristics. We achieved data saturation, coded the data in the language of the focus groups and used investigator triangulation in the analysis to ensure the themes reflected the breadth and depth of the data. However, there are some potential limitations. We are uncertain about the transferability of the findings to other countries with different healthcare policies on testing. We acknowledge that testing can be a sensitive topic and some views may have been suppressed in the focus group setting which may also explain why there was limited variation in the perspectives of caregivers versus patients. We discussed testing for disease presence only in patients diagnosed with ADPKD and 31% were receiving kidney replacement therapy. We acknowledge that the findings may not include views of at-risk persons because of ethical reasons. Other limitations include the relatively low number of caregivers and other subgroups (ie, transplant recipients) and being ethically unable to collect demographic characteristics from patients who declined to participate.

Our findings can inform ways to better inform and communicate with patients and their families. Knowledge of the available tests, prevention and management may support decision-making. Our findings support the value of genetic counsellors and education sessions prior to testing to help address the potential psychological and social consequences of testing to the individual and the family.45 Kidney Disease Improving Global Outcomes guidelines and the European ADPKD Forum suggest that patients with ADPKD should have access to reproductive counselling.29 48 However, as few as 20%–40% of nephrologists may actually inform their patients about the prenatal and preimplantation genetic diagnostic options due to ethical concerns while 68% of patients with ADPKD believe it should be offered.33 49 Clinicians have articulated similar concerns about testing for ADPKD because of the perceived absence of curative treatment options and the perceived minimal burden on QoL. However, perceptions of testing may change with increasing availability and use of vasopressin receptor antagonists to prevent the progression of ADPKD.50 Ongoing clinical trials may provide additional options for treatment to slow progression.51–53 Concerns about discrimination in regard to disclosure of genetic status should also be addressed.54

For some patients with ADPKD, testing could empower them to take charge of their health while for others, receiving a confirmed diagnosis of ADPKD causes unnecessary anxiety over a disease that they limited control over. Testing positive for ADPKD could jeopardise employment opportunities for patients and complicate family planning and dynamics. Providing access to education and genetic counselling in people at risk of ADPKD and their family, and psychosocial support after receiving the test results, are suggested to provide individuals with the capacity to make informed decisions and to empower them for self-management.

Acknowledgments

We are grateful to all the patients and their caregivers who generously gave their time to share their insights and perspectives.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Twitter @pkd_int, @KarineManera, @allisontong1

  • Contributors Conceptualisation: GKR, JC, AT, CL, YC. Methodology: JC, ATP, AT, CL, YC. Software: AT. Validation: CL, YC, BS, TG. Formal analysis: CL, YC, BS, ATP, AT, YC, TG. Investigation: CL, YC, BS, GKR, TG, JC, AO, AC, CA, HC, JTWK, RTG, RP, TH, VT, KF, YP, PK, JR, DJ, AV, CG, HK, YK, MH, AJ, KEM, ATP, GP, AT (all authors). Resources: AT. Data curation: YC, BS. Writing—original draft preparation: CL. Writing—review and editing: CL, YC, BS, GKR, TG, JC, AO, AC, CA, HC, JTWK, RTG, RP, TH, VT, KF, YP, PK, JR, DJ, AV, CG, HK, YK, MH, AJ, KEM, ATP, GP, AT (all authors). Visualisation: CL. Supervision: AT, GP, YC, JC. Project administration: TG, MH, AJ, KEM. Funding acquisition: AT, DJ, TG, MH, KEM, YC, AV, BS. All authors have read and agreed to the published version of the manuscript.

  • Funding The study was financially supported by a grant from Polycystic Kidney Disease Foundation of Australia and the National Health and Medical Research Council (NHMRC) Better Evidence and Translation in Chronic Kidney Disease (BEAT-CKD) Program (1092957), UMR INSERM 1246-SPHERE Methods in Patient-centered Outcomes and Health Research, and Research of Korea Center for Disease Control and Prevention (2016E3300201). AT is supported by an NHMRC Fellowship (1106716). DJ is supported by an NHMRC Practitioner Fellowship (1117534). TG is supported by an NHMRC Postgraduate Scholarship (1169149). MH is funded as a Post-Doctoral Fellow through the NHMRC BEAT-CKD Program Grant (APP1092957). KEM is supported by an NHMRC Postgraduate Scholarship (1151343). YC is supported by an NHMRC Early Career Fellowship (1126256). AV receives grant support from the NHMRC Medical Postgraduate Scholarship (1114539) and the Royal Australasian College of Physicians (Jacquot NHMRC Award for Excellence).

  • Competing interests GKR declares he is site investigator of clinical trials sponsored by Sanofi, Otsuka and Reata, principal investigator of the PREVENT-ADPKD clinical trial (funded in part by the NHMRC, Danone Nutricia—manufacturer of bottled water—PKD Australia, Westmead Medical Research Foundation) and Chair, Scientific Advisory Board, PKD Australia. RP declares he is site investigator of clinical trials sponsored by Sanofi, Kadmon, Reata, Otsuka and the US Department of Defense (TAME PKD), and section editor for Cystic Kidney Disease, UpToDate.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Patient consent for publication Not required.

  • Ethics approval The Human Research Ethics Committees of the Western Sydney Local Health District (HREC2009/6/4,14), Monash Medical Centre (2010.031), Metro South Health District (17/QPAH/112), France (INSERM/2017) and Republic of Korea (1709-097-886) approved this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No data are available. Data are available upon reasonable request to achieve aims in the approved proposal. Data include deidentified participant data and transcripts from focus groups that underlie the results reported in this article. The study protocol is also available. Data are available from the corresponding author (https://orcid.org/0000-0002-8773-1003).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.